CINJ 050703: A Phase Ib open-label, two-arm, dose-finding study of E7389 in combination with carboplatin in patients with solid tumours.
Phase of Trial: Phase I
Latest Information Update: 21 Jan 2019
At a glance
- Drugs Carboplatin; Eribulin
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Eisai Inc; Eisai Medical Research
- 24 May 2016 According to Eisai media release, data of this trial will be presented at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO), in June 2016.
- 13 Jul 2012 Status changed from recruiting to discontinued as reported by Clinical Trials Registry - India.
- 03 May 2011 Planned end date changed from 1 Jun 2012 to 1 Dec 2012 as reported by ClinicalTrials.gov.